Absci's ability to generate 'wet-lab data' gives it edge, Needham analsyst says. Shares in a Vancouver-based AI drug creation company Absci soared on Wednesday after an investment firm Needham ...
Needham analyst Gil Blum initiated coverage of Absci (ABSI) with a Buy rating and $9 price target Absci “stands out from the pack due to its ...
Truist Financial analyst Srikripa Devarakonda assigned a Buy rating to the stock today. The company’s shares closed last Friday at $2.90.Invest ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback